ClinicalTrials.gov
public full text
Public Domain
Efficacy and Safety Study of MAX-002 Suppository Versus Placebo and Active Medicine in Mild to Moderate Ulcerative Proctitis
This is a prospective, multicenter, double-blind (DB), controlled, randomized, parallel group comparison Phase 3a study to evaluate the efficacy and safety of new mesalamine suppositories (MAX-002) as compared to placebo and active medicine after 6 weeks of treatment in adults with mild to moderate ulcerative proctitis (UP).
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Management of Patients with Ulcerative Proctitis: a Global Survey#268711
- Short-Term Outcome of Medical Vs. Surgical Management Of Chronic Anal Fissure#838062
- Tacrolimus (FK506) P-III, Open-label Study in Refractory Ulcerative Colitis Patients#1058115
- Tacrolimus (FK506) Study in Moderate to Severe Refractory Ulcerative Colitis Patients#856350
- Study to Assess the Efficacy of Larazotide Acetate for the Treatment of Celiac Disease#1172839
Record · ID 1111733
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive